Modified Venetoclax Dose Ramp-Up in Select High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) with Progression after B-Cell Receptor Pathway Inhibitors (BCRi)

CLL patients who progress after BCRi can experience rapid progression after therapy discontinuation and have poor outcomes. The BCL-2 inhibitor venetoclax has demonstrated activity in these patients. Patients with high tumor burden and aggressive disease treated with standard 5-week venetoclax dose ramp-up, required to mitigate potential tumor lysis syndrome (TLS), may experience symptomatic disease progression during initial weeks of low-dose venetoclax.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matthew Davids, Jeffrey Jones, Herbert Eradat, Maria Verdugo, Jalaja Potluri, Richard R. Furman Source Type: research